Mayuko Sekiya

No ORCID on file · 2 papers in corpus
other 2026
Reply of the Authors: Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial
F&S reports ·doi:10.1016/j.xfre.2025.12.008
other 2025
Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial
F&S reports ·doi:10.1016/j.xfre.2025.04.009

OBJECTIVE: To evaluate the safety and pharmacokinetics/pharmacodynamics of AMY109, an anti-interleukin-8 recycling antibody in a first-in-human phase 1 trial in healthy volunteers (HVs) and patients with endometriosis. DESIGN: A multicente…